Cargando…
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1), has achieved remarkable success in a number of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827285/ https://www.ncbi.nlm.nih.gov/pubmed/35139879 http://dx.doi.org/10.1186/s13046-022-02273-w |